VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PETS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
PETSPetMed Express, Inc.
$1.82$39M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksPETSCash Flow

PetMed Express, Inc. (PETS) Cash Flow Statement

27Y historyFree accessUpdated daily

Cash flow generation remains volatile, with free cash flow margins plummeting to -51.8% in 2026Q2, highlighting a breakdown in operational cash conversion.

PETS Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricMar'26Mar'25Mar'24Mar'23Mar'22Mar'21Mar'20Mar'19Mar'18Mar'17Mar'16Mar'15Mar'14Mar'13Mar'12Mar'11Mar'10Mar'09Mar'08Mar'07Mar'06Mar'05Mar'04Mar'03Mar'02Mar'01Mar'00
Cash from Operations-28.39M4.72M4.32M27.8M18.5M40.08M38.84M45.14M37.38M47.2M21.05M32.04M13.51M13.29M20.39M30.11M27.69M14.97M19.38M16.56M10.28M8.35M1.11M970.3K476.02K-1.05M-317.24K
Operating CF Margin %-15.86%2.08%1.57%10.84%6.77%13.2%13.67%15.93%13.65%18.94%8.97%13.97%5.79%5.83%8.56%13%11.62%6.82%10.29%10.21%7.47%7.7%1.18%1.76%1.49%-10.46%-2.16%
Operating CF Growth %-701.82%9.29%-84.47%50.3%-53.84%3.17%-13.94%20.76%-20.81%124.22%-34.3%137.25%1.63%-34.82%-32.27%8.74%84.99%-22.78%17%61.17%23.1%655.14%13.94%103.83%145.48%-229.9%-
Net Income-57.29M-6.27M-7.46M233K21.1M30.6M25.85M37.74M37.28M23.82M20.57M17.45M17.97M17.16M16.66M20.87M26M22.98M20.02M14.44M12.06M8.01M5.81M3.26M825.41K-2.83M-1.79M
Depreciation & Amortization9.39M7.04M7.06M3.55M2.74M2.43M2.26M2.23M2.13M1.37M770K660K867K1.09M1.41M1.38M1.32M814.54K589.99K530.44K544.53K573.82K550.39K367.67K236.72K-88.29K-169.98K
Stock-Based Compensation1.36M-6.59M6.87M6.62M4.55M3.31M2.82M3.1M2.58M1.94M1.61M1.48M1.48M1.94M2.25M2.17M1.59M1.46M1.68M1.25K0000000
Deferred Taxes-88K5.25M292K-1.56M-345K311K-151K125K-92K1.95M-23K157K-183K-76K-56K348K-305.33K497.29K-327.31K-100.54K-211.16K-1.49K0-581.36K000
Other Non-Cash Items26.62M1.56M324K5.05M165K130K191K85K112K421K260K1.81M95K56K47K48K17.55K82.55K40.82K1.13M342.93K934.84K596.3K171.61K321.19K-19.01K610.5K
Working Capital Changes-8.39M3.72M-2.76M13.92M-9.71M3.3M7.87M1.87M-4.63M17.71M-2.13M10.48M-6.72M-6.89M84K5.29M-944.55K-10.87M-2.62M564.49K-2.46M-1.17M-5.85M-2.25M-907.3K1.89M1.04M
Change in Receivables445K601K-1.74M-41K509K1.13M-1.49M-335K-596K-505K-53K-264K-417K77K366K64K766.48K-1.38M-246.56K00000000
Change in Inventory471K12.35M-6.42M13.43M1.97M-16.54M3.49M1.97M-3.11M5.36M-518K10.66M-4.13M-5.38M-1.08M3.92M-2.29M-8.87M-1.82M-1.09M-3.82M-475-6.91M-1.96M-1.68M1.12M-175.98K
Change in Payables-2.66M-13.46M6.1M-2.29M-12.05M19.89M3.38M1M53K10.22M-149K-616K-686K-165K297K1.96M312.77K-313.44K-1.5M00000000
Cash from Investing-4.62M-5.11M-40.67M-10.26M-1.75M-2.43M-2.31M-620K-703K-10.6M-4.49M-986K-129K-5.82M11.64M-10.82M1.1M11.18M9.1M-17.3M-757.58K-171.76K-741.74K-1.09M1.46M69.54K-918.18K
Capital Expenditures-4.62M-5.11M-4.51M-5.26M-1.75M-2.43M-2.31M-620K-703K-10.6M-20.13M-918K-45K-626K-705K-677K-1.05M-3.69M-502.71K-1.03M-758.18K-171.76K-741.74K-744.6K-555.64K-241.89K-552.1K
CapEx % of Revenue2.58%2.25%1.65%2.05%0.64%0.8%0.81%0.22%0.26%4.26%8.58%0.4%0.02%0.27%0.3%0.29%0.44%1.68%0.27%0.63%0.55%0.16%0.79%1.35%1.74%2.42%3.76%
Acquisitions00-36.16M-5M00000000000000000000000
Investments---------------------------
Other Investing0005M00000015.64M-68K-84K-5.19M12.34M-10.15M2.15M2K9.61M40060000-350K2.02M311.43K-366.08K
Cash from Financing-299K-181K-12.44M-24.54M-24.38M-22.69M-33.3M-21.93M-17.47M-15.51M-14.54M-13.75M-13.23M-36.12M-34.89M-22.77M-5.77M-16.29M-8.53M684.8K1.02M1.22M1.93M371.18K-1.61M1.07M861.52K
Debt Issued (Net)000000000000000000000-68.44K-68.44K-209.66K-1.61M-879.25K604.52K
Equity Issued (Net)000000-11.5M000000-3.87M-23.68M-12.25M0-18.45M-11.6M442.08K1.02M1.29M2M580.84K01.95M257K
Dividends Paid-21K-181K-12.44M-24.54M-24.38M-22.69M-21.8M-21.93M-17.47M-15.51M-14.68M-13.81M-13.33M-31.97M-10.96M-10.73M-6.81M0000000000
Share Repurchases000000-11.5M00000-3.87M-3.87M-23.68M-12.25M0-18.45M-11.6M000000-1K0
Other Financing-278K000000000142K58K99K-284K-240K208K1.03M2.16M3.07M242.72K0000000
Net Change in Cash-33.31M-576K-48.79M-6.99M-7.64M14.96M3.23M22.59M19.21M21.09M2.03M17.31M150K-28.65M-2.86M-3.48M23.02M9.86M19.95M-50.44K10.54M9.4M2.29M246.88K328.58K96.85K-373.9K
Free Cash Flow-33.01M-395K-194K22.54M16.75M37.64M36.53M44.52M36.68M36.6M923K31.13M13.46M12.66M19.69M29.43M26.64M11.27M18.88M15.54M9.52M8.18M363.86K225.71K-79.62K-1.29M-869.34K
FCF Margin %-18.44%-0.17%-0.07%8.79%6.12%12.4%12.86%15.71%13.4%14.69%0.39%13.57%5.77%5.56%8.26%12.7%11.18%5.14%10.02%9.58%6.92%7.55%0.39%0.41%-0.25%-12.88%-5.92%
FCF Growth %-8256.71%-103.61%-100.86%34.62%-55.51%3.04%-17.94%21.38%0.21%3865.33%-97.03%131.22%6.29%-35.67%-33.11%10.47%136.3%-40.28%21.48%63.24%16.42%2147.34%61.21%383.47%93.82%-48.21%-
FCF per Share-1.58-0.02-0.011.110.821.871.822.171.791.800.051.550.670.630.951.301.170.480.780.640.390.340.020.01-0.00-0.13-0.14
FCF Conversion (FCF/Net Income)0.50x-0.75x-0.58x5.41x0.88x1.68x1.50x1.20x1.00x1.98x1.02x1.84x0.75x0.77x1.22x1.44x1.06x0.65x0.97x1.15x0.85x1.04x0.19x0.30x0.58x0.37x0.18x
Interest Paid000000000000000000000000000
Taxes Paid52K0130K4.31M6.08M10.02M7.14M11.05M18.05M11.37M12.17M10.03M10.73M10.14M9.54M12.58M14.72M16.46M10.33M00000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Liquidity and customer churn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q4)

Earnings and Cash Flow Disconnect

As reported in quarterly financial filings, the relationship between net income and operating cash flow has become increasingly erratic, with OCF/NI ratios swinging from 3.18 in 2025Q2 to -2.27 in 2025Q1, indicating a lack of reliable cash conversion quality during this period of operational contraction.

The extreme volatility in the OCF/NI ratio suggests that reported net income is being heavily distorted by non-cash items or significant working capital swings. Investors should monitor whether this divergence reflects genuine operational friction or accounting adjustments that mask the underlying cash-generating capacity of the pharmacy business.

Free Cash Flow Margin Erosion

Based on the provided cash flow data, PETS has seen its FCF margins deteriorate significantly, plummeting to a low of -51.8% in 2026Q2, which underscores the company's inability to maintain positive cash generation as revenue declines and operating costs remain stubbornly high.

The trajectory of FCF is clearly negative, moving from intermittent positive quarters to sustained outflows. This trend suggests that the current business model is no longer self-funding, necessitating a potential reliance on existing cash reserves that are rapidly depleting.

Working Capital Volatility Signals Instability

According to recent financial statements, working capital changes have been highly inconsistent, oscillating between a $7.6M inflow in 2024Q4 and a $3.4M outflow in 2026Q3, which suggests that the company is struggling to manage its inventory and payables effectively amidst a shrinking customer base.

The erratic nature of these working capital shifts may indicate difficulty in aligning inventory procurement with actual demand. Such instability often precedes further margin pressure as the company may be forced to liquidate slow-moving inventory at unfavorable prices to preserve liquidity.

SBC and Non-Cash Expense Obfuscation

As indicated by the provided data, stock-based compensation has fluctuated wildly, reaching a negative $8.2M in 2025Q1 and a positive $7.2M in 2025Q4, which complicates the assessment of true cash-based operating performance and obscures the actual cost of talent retention.

The significant swings in SBC suggest that management's compensation structure is not consistently aligned with the company's deteriorating financial performance. Analysts should be wary of these adjustments, as they appear to artificially inflate or deflate cash flow metrics in ways that do not reflect the core business reality.

PETS — Frequently Asked Questions

Quick answers to the most common questions about buying PETS stock.

How much cash does PetMed Express, Inc. (PETS) generate from operations?

PetMed Express, Inc. (PETS) generated $-28.4M in net cash from operating activities in 2026. This reflects the cash generated directly from core business operations.

What is PetMed Express, Inc.'s free cash flow?

PetMed Express, Inc. (PETS) reported negative free cash flow of $33.0M in 2026, indicating capital requirements exceeded cash from operations.

What is PetMed Express, Inc.'s capital expenditure (CapEx)?

PetMed Express, Inc. (PETS) spent $4.6M on capital expenditures in 2026. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does PetMed Express, Inc. distribute cash to shareholders?

In 2026, PetMed Express, Inc. (PETS) returned $0.0M to shareholders via cash dividends. This shows the company's commitment to returning capital to its equity investors.